SuperworthUltragenyx Pharmaceutical shares outstanding RARE
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Jun 30, 2026
- 101.9M
- On a year earlier
- +3.5%
- more shares
Ultragenyx Pharmaceutical had 101.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 3.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 99.8M | +4% |
| FY2024 | 95.7M | +18% |
| FY2023 | 81.1M | +16% |
| FY2022 | 70.2M | +2% |
| FY2021 | 68.6M | +6% |
| FY2020 | 64.7M | +12% |
| FY2019 | 57.8M | +14% |
| FY2018 | 50.7M | +18% |
| FY2017 | 43.1M | +6% |
| FY2016 | 40.8M | +5% |
| FY2015 | 38.8M | +22% |
| FY2014 | 31.9M | +752% |
| FY2013 | 3.7M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 101.9M | +3% | |
| Q1 FY26 | 100.6M | +4% | |
| Q4 FY25 | 99.8M | +4% | |
| Q3 FY25 | 99.8M | +4% | |
| Q2 FY25 | 98.5M | +14% | |
| Q1 FY25 | 96.3M | +14% | |
| Q4 FY24 | 95.7M | +18% | |
| Q3 FY24 | 95.5M | +33% | |
| Q2 FY24 | 86.6M | +22% | |
| Q1 FY24 | 84.3M | +20% | |
| Q4 FY23 | 81.1M | +16% | |
| Q3 FY23 | 71.7M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Ultragenyx Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.